|
1
|
Venook AP, Niedzwiecki D, Lenz HJ,
Innocenti F, Mahoney MR, O'Neil BH, Shaw JE, Polite BN, Hochster
HS, Atkins JN, et al: CALGB/SWOG 80405: Phase III trial of
irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin
(mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients
(pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma
of the colon or rectum (MCRC). J Clin Oncol. 32 Suppl:52014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siriwardena AK, Mason JM, Mullamitha S,
Hancock HC and Jegatheeswaran S: Management of colorectal cancer
presenting with synchronous liver metastases. Nat Rev Clin Oncol.
11:446–459. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kopetz S, Chang GJ, Overman MJ, Eng C,
Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM and
McWilliams RR: Improved survival in metastatic colorectal cancer is
associated with adoption of hepatic resection and improved
chemotherapy. J Clin Oncol. 27:3677–3683. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fong Y, Fortner J, Sun RL, Brennan MF and
Blumgart LH: Clinical score for predicting recurrence after hepatic
resection for metastatic colorectal cancer: Analysis of 1001
consecutive cases. Ann Surg. 230:3093211999. View Article : Google Scholar
|
|
6
|
Gayowski TJ, Iwatsuki S, Madariaga JR,
Selby R, Todo S, Irish W and Starzl TE: Experience in hepatic
resection for metastatic colorectal cancer: Analysis of clinical
and pathologic risk factors. Surgery. 116:703–711. 1994.PubMed/NCBI
|
|
7
|
Kato T, Yasui K, Hirai T, Kanemitsu Y,
Mori T, Sugihara K, Mochizuki H and Yamamoto J: Therapeutic results
for hepatic metastasis of colorectal cancer with special reference
to effectiveness of hepatectomy: Analysis of prognostic factors for
763 cases recorded at 18 institutions. Dis Colon Rectum 46 (10
Suppl). 1–31. 2003.
|
|
8
|
Nordlinger B, Guiguet M, Vaillant JC,
Balladur P, Boudjema K, Bachellier P and Jaeck D: Surgical
resection of colorectal carcinoma metastases to the liver. A
prognostic scoring system to improve case selection, based on 1568
patients. Association Française de Chirurgie. Cancer. 77:1254–1262.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Viganò L, Capussotti L, Majno P, Toso C,
Ferrero A, De Rosa G, Rubbia-Brandt L and Mentha G: Liver resection
in patients with eight or more colorectal liver metastases. Br J
Surg. 102:92–101. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wei AC, Greig PD, Grant D, Taylor B,
Langer B and Gallinger S: Survival after hepatic resection for
colorectal metastases: A 10-year experience. Ann Surg Oncol.
13:668–676. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yi JH, Kim H, Jung M, Shin SJ, Choi JS,
Choi GH, Baik SH, Min BS, Kim NK and Ahn JB: Prognostic factors for
disease-free survival after preoperative chemotherapy followed by
curative resection in patients with colorectal cancer harboring
hepatic metastasis: A single-institute, retrospective analysis in
Asia. Oncology. 85:283–289. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Antoch G, Kanja J, Bauer S, Kuehl H,
Renzing-Koehler K, Schuette J, Bockisch A, Debatin JF and
Freudenberg LS: Comparison of PET, CT, and dual-modality PET/CT
imaging for monitoring of imatinib (STI571) therapy in patients
with gastrointestinal stromal tumors. J Nucl Med. 45:357–365.
2004.PubMed/NCBI
|
|
13
|
Stroobants S, Goeminne J, Seegers M,
Dimitrijevic S, Dupont P, Nuyts J, Martens M, Van den Borne B, Cole
P, Sciot R, et al: 18FDG-Positron emission tomography for the early
prediction of response in advanced soft tissue sarcoma treated with
imatinib mesylate (Glivec). Eur J Cancer. 39:2012–2020. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Blanke CD, Demetri GD, von Mehren M,
Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD,
Roberts PJ, Heinz D, et al: Long-term results from a randomized
phase II trial of standard-versus higher-dose imatinib mesylate for
patients with unresectable or metastatic gastrointestinal stromal
tumors expressing KIT. J Clin Oncol. 26:620–625. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC, et al: New guidelines to evaluate the
response to treatment in solid tumors. european organization for
research and treatment of cancer, national cancer institute of the
United States, national cancer institute of Canada. J Natl Cancer
Inst. 92:205–216. 2000. View Article : Google Scholar
|
|
16
|
Chun YS, Vauthey JN, Boonsirikamchai P,
Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Kaur H,
Charnsangavej C and Loyer EM: Association of computed tomography
morphologic criteria with pathologic response and survival in
patients treated with bevacizumab for colorectal liver metastases.
Jama. 302:2338–2344. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nishioka Y, Shindoh J, Yoshioka R, Gonoi
W, Abe H, Okura N, Yoshida S, Oba M, Hashimoto M, Watanabe G, et
al: Radiological morphology of colorectal liver metastases after
preoperative chemotherapy predicts tumor viability and
postoperative outcomes. J Gastrointest Surg. 19:1653–1661. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shindoh J, Loyer EM, Kopetz S,
Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA,
Charnsangavej C, Aloia TA and Vauthey JN: Optimal morphologic
response to preoperative chemotherapy: An alternate outcome end
point before resection of hepatic colorectal metastases. J Clin
Oncol. 30:4566–4572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Klinger M, Tamandl D, Eipeldauer S, Hacker
S, Herberger B, Kaczirek K, Dorfmeister M, Gruenberger B and
Gruenberger T: Bevacizumab improves pathological response of
colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann
Surg Oncol. 17:2059–2065. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
O'Connor JP, Carano RA, Clamp AR, Ross J,
Ho CC, Jackson A, Parker GJ, Rose CJ, Peale FV, Friesenhahn M, et
al: Quantifying antivascular effects of monoclonal antibodies to
vascular endothelial growth factor: Insights from imaging. Clin
Cancer Res. 15:6674–6682. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Choi H, Charnsangavej C, Faria SC,
Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA and
Benjamin RS: Correlation of computed tomography and positron
emission tomography in patients with metastatic gastrointestinal
stromal tumor treated at a single institution with imatinib
mesylate: Proposal of new computed tomography response criteria. J
Clin Oncol. 25:1753–1759. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shindoh J, Chun YS, Loyer EM and Vauthey
JN: Non-size-based response criteria to preoperative chemotherapy
in patients with colorectal liver metastases: The morphologic
response criteria. Curr Colorectal Cancer Rep. 9:198–202. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schmoll HJ, Van Cutsem E, Stein A,
Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde
CJ, Balmana J, Regula J, et al: ESMO consensus guidelines for
management of patients with colon and rectal cancer. a personalized
approach to clinical decision making. Ann Oncol. 23:2479–2516.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
NCCN Clinical Practice Guidelines in
Oncology: Colon Cancer. http://www.nccn.org/professionals/physician_gls/f_guidelines.aspJanuary
1–2016
|
|
25
|
Benoist S, Brouquet A, Penna C, Julié C,
El Hajjam M, Chagnon S, Mitry E, Rougier P and Nordlinger B:
Complete response of colorectal liver metastases after
chemotherapy: Does it mean cure? J Clin Oncol. 24:3939–3945. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoshita H, Hosokawa A, Ueda A, Ando T,
Kajiura S, Kato H, Kawabe H, Tomizawa G, Horikawa N, Yabuhita K, et
al: Predictive value of optimal morphologic response to first-line
chemotherapy in patients with colorectal liver metastases.
Digestion. 89:pp. 43–48. 2014; View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Garden OJ, Rees M, Poston GJ, Mirza D,
Saunders M, Ledermann J, Primrose JN and Parks RW: Guidelines for
resection of colorectal cancer liver metastases. Gut. 55 Suppl
3:iii1–8. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stangl R, Altendorf-Hofmann A, Charnley RM
and Scheele J: Factors influencing the natural history of
colorectal liver metastases. Lancet. 343:1405–1410. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schwartzberg LS, Rivera F, Karthaus M,
Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS and Go WY: PEAK: A
randomized, multicenter phase II study of panitumumab plus modified
fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) or bevacizumab
plus mFOLFOX6 in patients with previously untreated, unresectable,
wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol.
32:2240–2247. 2014. View Article : Google Scholar : PubMed/NCBI
|
